IDM Pharma to Present at Rodman and Renshaw 8th Annual Healthcare Conference

Strategic Insights -

IDM Pharma, a biopharmaceutical company focused on developing innovative cancer treatments, will present at the Rodman and Renshaw 8th Annual Healthcare Conference in New York City. Jean-Loup Romet-Lemonne, M.D., CEO of IDM Pharma, will provide a corporate overview and update on the company's product candidates, including its five products in clinical development, one of which has already filed a New Drug Application (NDA) for the treatment of osteosarcoma. IDM Pharma's partnership with SANOFI-AVENTIS in cancer immunotherapy has been a significant driver of the company's growth. The presentation will be available on IDM Pharma's website for investors and those interested in learning more about the company's progress.

Key Takeaways:

  • IDM Pharma is a biopharmaceutical company developing innovative products that activate the immune system to treat cancer.
  • The company has five products in clinical development, including Junovan(TM) for the treatment of osteosarcoma, which has filed a NDA.
  • Three products are in Phase II clinical trials in bladder cancer, melanoma, and non-small cell lung cancer, and one is in Phase I in colorectal cancer.
  • IDM Pharma has a major product development partnership with SANOFI-AVENTIS in cancer immunotherapy.
  • The partnership with SANOFI-AVENTIS and MEDAREX dates back to 1993 and 2001, respectively.
  • IDM Pharma's presentation at the Rodman and Renshaw conference will be available on the company's website.

Statistics:

  • 5 products in clinical development (IDM Pharma)
  • 1 NDA filed for Junovan(TM) in the treatment of osteosarcoma (IDM Pharma)
  • 3 products in Phase II clinical trials (IDM Pharma)

+ Bladder cancer

+ Melanoma

+ Non-small cell lung cancer

  • 1 product in Phase I clinical trial (IDM Pharma) - colorectal cancer
  • Partnership with SANOFI-AVENTIS since 2001 (IDM Pharma)
  • Partnership with MEDAREX since 1993 (IDM Pharma)

Sources:

  • IDM Pharma (press release dated November 7, 2006)
  • IDM Pharma's website (www.idm-pharma.com)
  • Rodman and Renshaw website (www.rodmanandrenshaw.com)